The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia.
- Author:
Young Joo MIN
1
;
Cheol Won SUH
;
Keon Uk PARK
;
Sung Soo YOON
;
Chan Hyung PARK
;
Hong Ghi LEE
Author Information
1. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Publication Type:Original Article
- Keywords:
Acute myelogenous leukemia;
rhG-CSF;
Neutropenia
- MeSH:
Cytarabine;
Drug Therapy*;
Granulocyte Colony-Stimulating Factor;
Granulocytes*;
Headache;
Humans*;
Idarubicin;
Leukemia, Myeloid, Acute*;
Neutropenia*;
Neutrophils;
Remission Induction*
- From:Cancer Research and Treatment
2003;35(1):66-68
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML). MATERIALS AND METHODS: After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days. RESULTS: The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%). CONCLUSION: The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.
